Several other research analysts also recently weighed in on XLRN. BidaskClub upgraded shares of Acceleron Pharma from a hold rating to a buy rating in a research report on Wednesday, December 27th. Royal Bank of Canada initiated coverage on shares of Acceleron Pharma in a research report on Thursday, September 14th. They set a sector perform rating and a $44.00 price target for the company. UBS Group restated a buy rating and set a $50.00 price target (up previously from $36.00) on shares of Acceleron Pharma in a research report on Tuesday, September 12th. ValuEngine downgraded shares of Acceleron Pharma from a hold rating to a sell rating in a research report on Friday, October 6th. Finally, HC Wainwright upped their price target on shares of Acceleron Pharma from $57.00 to $62.00 and gave the stock a buy rating in a research report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $44.56.
Shares of Acceleron Pharma (XLRN) traded up $1.21 during trading on Monday, hitting $45.12. 666,800 shares of the company’s stock were exchanged, compared to its average volume of 359,233. The firm has a market capitalization of $1,990.00, a P/E ratio of -17.49 and a beta of 1.59. Acceleron Pharma has a 1-year low of $23.07 and a 1-year high of $45.52.
In other news, SVP Christopher Rovaldi sold 2,266 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $42.42, for a total value of $96,123.72. Following the completion of the sale, the senior vice president now owns 52,977 shares of the company’s stock, valued at approximately $2,247,284.34. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jean George sold 105,122 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $35.73, for a total transaction of $3,756,009.06. Following the completion of the sale, the director now directly owns 1,250 shares of the company’s stock, valued at approximately $44,662.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 135,021 shares of company stock valued at $5,034,598. 3.90% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the stock. Quantbot Technologies LP boosted its position in shares of Acceleron Pharma by 416.3% during the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,352 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in Acceleron Pharma by 969.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 3,288 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Acceleron Pharma during the 3rd quarter worth approximately $225,000. Trexquant Investment LP acquired a new stake in Acceleron Pharma during the 3rd quarter worth approximately $266,000. Finally, PNC Financial Services Group Inc. lifted its holdings in Acceleron Pharma by 57.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 3,100 shares in the last quarter. 85.70% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Acceleron Pharma’s (NASDAQ:XLRN) “Hold” Rating Reiterated at Oppenheimer” was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/acceleron-pharma-xlrn-receives-hold-rating-from-oppenheimer/1821117.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.